Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GBS-NN/NN2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : MinervaX ApS
Deal Size : Undisclosed
Deal Type : Collaboration
MinervaX and Wacker Partner On Group B Strep Vaccine Manufacturing
Details : The collaboration aims to manufacture MinervaX's active protein ingredients of its GBS vaccine, GBS NN, a novel, prophylactic vaccine against Group B Streptococcus.
Brand Name : GBS-NN/NN2
Molecule Type : Vaccine
Upfront Cash : Undisclosed
September 17, 2024
Lead Product(s) : GBS-NN/NN2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : MinervaX ApS
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : PAN004
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Pantherna Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Wacker and Pantherna Enhance Collaboration in mRNA Biopharmaceutical Development
Details : Through the collaboration, company aims to focus on the clinical development of PAN004, which is being evaluated in the preclinical studies for the treatment of acute respiratory distress syndrome.
Brand Name : PAN004
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 07, 2024
Lead Product(s) : PAN004
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Pantherna Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : CTR-107
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Caeregen Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims for the development and production of Noregen (CTR-107), a novel regenerative therapeutic, for treating retinal-related vision loss. CTR-107 is the first program to obtain FDA Rare Pediatric Disease Designation for Familial Exudati...
Brand Name : Noregen
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 28, 2023
Lead Product(s) : CTR-107
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Caeregen Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : CVnCoV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : CureVac
Deal Size : Undisclosed
Deal Type : Agreement
CureVac and WACKER Sign Manufacturing Contract for CureVac’s COVID-19 Vaccine Candidate, CVnCoV
Details : Under the terms of the initial agreement, WACKER will ramp up GMP (Good Manufacturing Practice) production of the mRNA drug substance for CVnCoV at its biotech site in Amsterdam in the first half of 2021.
Brand Name : CVnCoV
Molecule Type : Vaccine
Upfront Cash : Undisclosed
November 23, 2020
Lead Product(s) : CVnCoV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : CureVac
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?